Diltiazem and progression of myocardial ischemic damage during coronary artery occlusion and reperfusion in porcine hearts

Servicio de Cardiologia, Hospital Provincial de Madrid, Spain.

This study was designed to investigate whether a cardioprotective intervention could delay the completion of necrosis so that subsequent reperfusion would be more useful. Thirty-six pigs were randomly allocated to treatment with diltiazem (15 micrograms/kg per min) or saline solution and to a 60 or 120 minute coronary occlusion period followed by reperfusion. The treatment was begun 15 minutes before coronary occlusion and terminated 75 minutes after reperfusion. Twenty-four hours after the procedure, the heart was sliced and incubated in triphenyltetrazolium chloride. The infarct area and the maximal transmural area of extension of the infarct were calculated by planimetry. The total number of red blood cells in a transmural section was also counted. In the pigs with a 60 minute coronary occlusion, diltiazem (compared with saline solution) significantly reduced infarct size from 9.7 +/- 1.5% of left ventricular mass to 5.9 +/- 0.6% (p less than 0.05) and the percent transmural extension from 0.72 +/- 0.05 to 0.61 +/- 0.05% (p less than 0.05). Red blood cell extravasation in the infarcted area was reduced from 161,934 +/- 59,905 to 78,525 +/- 46,484 cells/mm3 (p less than 0.05) with diltiazem and the percent transmural extension of the hemorrhagic necrosis from 70 +/- 10 to 36 +/- 15% (p less than 0.05). No such differences were observed in the 120 minute coronary occlusion groups. Mean red blood cell counts and the extent of hemorrhagic necrosis did not correlate with either infarct size or transmural extension.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF]

				Q.-D. Wang, J. Pernow, P.-O. Sjoquist, and L. Ryden Pharmacological possibilities for protection against myocardial reperfusion injury Cardiovasc Res, July 1, 2002; 55(1): 25 - 37. [Abstract] [Full Text] [PDF]

				L. Ryden, P.-O. Sjoquist, and Q.-D. Wang Pharmacological tools for the limitation of myocardial reperfusion injury: Experimental evidence Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C28 - C35. [Abstract] [PDF]

				R. Schulz, H. Post, A. Jalowy, U. Backenkohler, H. Dorge, C. Vahlhaus, and G. Heusch Unique Cardioprotective Action of the New Calcium Antagonist Mibefradil Circulation, January 19, 1999; 99(2): 305 - 311. [Abstract] [Full Text] [PDF]

				P. Theroux, J. Gregoire, C. Chin, G. Pelletier, P. de Guise, and M. Juneau Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial J. Am. Coll. Cardiol., September 1, 1998; 32(3): 620 - 628. [Abstract] [Full Text] [PDF]